A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.
Relapsed/Refractory Multiple Myeloma: Targeted Therapy and BCMA
Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.
Dr Sagar Lonial, MD, FACP, comments on BCMA as a potential therapeutic target for multiple myeloma.
A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.
Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.
Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
3
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
